NovaPharm Healthcare
Medicine. Where it needs to be.
Qualified sourcing, regulatory readiness and controlled B2B supply-chain development for the UK pharmaceutical market.
Conceptual supply-chain visual. No NovaPharm facility, vehicle, inventory or current distribution activity is depicted.
Why NovaPharm
Pharmaceutical opportunity should move no faster than the evidence behind it.
NovaPharm is building a B2B model that connects product rights, qualified sources, regulatory scope, quality governance and commercial judgement before release.
Sourcing strategy
Three routes. One evidence standard.
Each route is assessed independently. None bypasses product-specific rights, quality or regulatory review.
- 01
Direct GMP partnerships
Qualified manufacturer relationships supported by technical assessment, vendor qualification and appropriate agreements.
- 02
Product-specific PLPI
Evidence-led assessment of suitable opportunities, subject to the applicable MHRA route and continuing obligations.
- 03
European sourcing
Diversified authorised supply routes reviewed for licence standing, quality, provenance and continuity.
Regulatory foundation
Permission, quality and product responsibility must align before release.
The pathway makes sequence and accountability visible without suggesting that an application or approval has already been granted.
- 01WDA(H) application readiness
- 02Product-specific PLPI assessment
- 03QMS and SOP governance
- 04GDP and vendor oversight
- 05Pharmacovigilance and recall readiness
- 06Batch and document integrity
- 07Commercial release only after applicable authorisation
Oncology
Continuity begins before a product moves.
Formulation, evidence, source, condition control and accountable hand-offs need to be considered as one system.
Nutraxin
Nineteen catalogue references. Presented as products, governed as evidence.
Approved pack imagery and source-transcribed composition support qualified B2B review. Availability, price, stock and claims are not asserted.
Technology
Use the smallest system that preserves control.
NovaPharm separates what is live, what is in development and what remains planned.
Public corporate platform
Approved public information, entity records and governed publication controls.
Managed workflows
Secure account, document and role-based services requiring production authority.
Data-assisted operations
Future forecasting and traceability capabilities subject to governed data and validation.
Qualified collaboration
Different organisations. One disciplined route into partnership.
NovaPharm is designed for evidence-led conversations with organisations that can establish their role, authority and intended scope.
- GMP manufacturers and CMO/CDMOs
- Product and dossier owners
- Marketing-authorisation holders
- Authorised pharmaceutical wholesalers
- Pharmacies and hospital procurement teams
- Quality, regulatory, logistics and technology specialists
Qualified conversations
Bring the opportunity. We will start with the evidence.
B2B only. A conversation, enquiry or application does not confirm approval, availability or permission to supply.